Navigation Links
Adis Journals Make Impressive Impact Factor Gains
Date:7/18/2011

YARDLEY, Pa., July 18, 2011 /PRNewswire/ -- Wolters Kluwer Pharma Solutions, Inc., a leading provider of scientific information and analytics to pharmaceutical and healthcare professionals, today announced strong impact factor (IF) gains for its Adis line of drug therapy and patient management journals.  11 of the 13 Adis journals that carried IFs in 2009 bettered their performance in 2010 according to the annual Journal Citation Reports® published in June.The most impressive gains over 2009 were made by PharmacoEconomics (IF 3.44) – up 34 percent to become the leading Health Outcomes Research journal, and Sports Medicine (IF 5.072) - up 63 percent, also becoming the highest ranking title in its field.

Drugs in R&D (IF 1.707), re-launched in 2010 as Adis' first fully open access MEDLINE-indexed journal gained 26 percent. Other standout performers include CNS Drugs (IF 4.497) - up 16 percent and Biodrugs (IF 4.192) – up 20 percent.  

"The price of Adis journals was significantly restructured at the end of 2009 providing affordable access for a wider group of customers," said Iain Spray, Adis Product Manager, Wolters Kluwer Pharma Solutions.  "These IF gains are partly the result of that increased access, and the continued determination of our editors, editorial boards and publishing team to strive for the highest level of quality."

An impact factor quantifies the relative influence of a scholarly journal in its scientific field.  It is a measure of the frequency with which the average article in a journal has been cited in a given year.

For more than 40 years, medical and scientific researchers have turned to Adis for its high quality, peer-reviewed content. Adis journals, covering the evidence-based pharmacology spectrum from clinical pharmacology to drug development and drug safety, to pharmacoeconomics, medical biotechnology and disease management, are available on AdisOnline (http://adisonline.com).  

For more information, visit the company's website at www.wolterskluwerpharma.com.

About Wolters Kluwer Pharma SolutionsWolters Kluwer Pharma Solutions, Inc. (Phoenix, AZ and Yardley, PA) is a leading provider of information and analytics to the pharmaceutical, biotech, and medical device industries. The company's brands include Adis, Source® and Lippincott Williams & Wilkins. A provider of business intelligence and services, Adis publishes 19 peer-reviewed drug research journals and 2 newsletters and offers the most respected drug and clinical trials databases in the pharma industry. Lippincott Williams & Wilkins (LWW) is a leading international healthcare publisher with nearly 300 periodicals and 1,500 books in more than 100 disciplines. A longstanding provider of market data and healthcare analytics, Source® offers a unique set of comprehensive patient and physician-level prescribing and usage data. For more information, visit www.wolterskluwerpharma.com.

The company is a wholly owned subsidiary of Wolters Kluwer, U.S., part of Wolters Kluwer, a market-leading global information services company. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance, and healthcare rely on Wolters Kluwer's leading, information-enabled tools and solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.

Wolters Kluwer has 2010 annual revenues of euro 3.6 billion ($4.7 billion), employs approximately 18,200 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices.Contact:

Tom KivettKivett & Company Communications+1 212 727-2935tkivett@kivettandco.com
'/>"/>

SOURCE Wolters Kluwer Pharma Solutions, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Adis Journals Embrace Open Access
2. Reprints Desk Bolsters Ultra-Rapid Document Delivery Service Through New Electronic Sourcing Agreement with the American Medical Association, Publisher of JAMA & Archives Journals
3. American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation
4. Data Presented at ACC/i2 Summit Demonstrate Impressive Long Term Clinical Outcomes in Real World Patients Treated with OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
5. Abbotts XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
6. Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
7. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
8. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
9. ImpactRx Measures How Patient Brand Requests Drive Physician Treatment Decisions
10. Update on IMPACT Study Results
11. Two Studies Test Impact of Drugs to Slow Progression of Type 1 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... May 24, 2016  Diana Russell suffers from a ... from the inside out.  This disease has put her ... her children and grandchildren to leave her home.  Because ... family cannot haul the wheelchair.  So if there is ... and Diana is left to wait for the bus. ...
(Date:5/24/2016)... 2016 The innovator of ... , s first dual therapy stent, introduces catheters ... OrbusNeich, a global company specializing in the provision ... include products to treat peripheral artery disease. The JADE™ ... devices for lower limb and arteriovenous (AV) fistula intervention. ...
(Date:5/24/2016)... Een app die artsen over de hele ... behandelen, hun kennis kunnen delen en van elkaar kunnen ... revolutionaire MDLinking App, ontwikkeld door een internationale groep artsen ... en oncologisch chirurg dr. Gijs van Acker . ... dinsdag 24 mei officieel gepresenteerd op het Amsterdam Startup ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... Leadership of Life ... announced the organization has earned its ISO 13485 certification, indicating the company’s quality ... all rules and policies associated with ISO quality standard 13485. , BSI ...
(Date:5/26/2016)... ... ... North Cypress Medical Center hosted its 9th Annual Spring Classic Golf ... of community partners, the event organizers raised $45,000 for the Lone Survivor Foundation ... their families through health, wellness, and therapeutic support. , A special military three-plane ...
(Date:5/26/2016)... ... , ... The MIAMI Institute for Age Management and Intervention celebrates Global Wellness ... Dr. Adonis , Wellness Physician of the MIAMI Institute is certified by the ... Functional Medicine. , He also heads up FITTLab, the comprehensive medical testing lab located ...
(Date:5/26/2016)... ... May 26, 2016 , ... Bunion Bootie , the manufacturer ... treatment was more than humbled by customer demand over the Mother’s Day Weekend promotion. ... sale. Now that Bunion Bootie has completely replenished its inventory levels, it hopes to ...
(Date:5/26/2016)... ... May 26, 2016 , ... A health conscious snack that ... Dough Bar, has ignited an undeniable buzz in the protein product community by ... just any doughnut.  These doughnuts are packed with 11 grams of protein and made ...
Breaking Medicine News(10 mins):